Gates-Bridge broker reveals: Is Biogen's Latest Alzheimer's Drug Approval a Good Reason to Invest in Its Stock?

By meghana_awhale | Date: 24/01/2323

London, uk -- Gates-Bridge broker says that since the dawn of modern medicine, it has been a dream to find a cure for Alzheimer's disease. In the last few decades, researchers have made tremendous progress towards finding a way to treat this debilitating illness successfully. And now, in 2023, Biogen has just received acceptance from the Food and Drug Administration (FDA) for the latest drug to treat Alzheimer's: Aducanumab.

If Leqembi is approved for Medicare reimbursement, Biogen will have an excellent opportunity to capitalize on the market. Eisai's drug pricing at $26,500 annually is significantly lower than its estimated per-patient societal value of $37,600. This pricing strategy could open up a substantial segment of the population that was previously unable to access the medication.

The potential of Leqembi gaining Medicare coverage could lead to increased sales and market share. This is especially important as it could increase the number of patients with access to the medicine, thus improving the lives of those suffering from the condition. Furthermore, the reduced drug cost could also help reduce overall healthcare costs as patients can access the medication more efficiently.

It is projected that within the next three years, approximately 100,000 patients in the U.S. will be utilizing Leqembi. This would equate to a total of $2.65 billion in sales based on the current market price for the medication. This figure is a significant increase from the number of individuals who would otherwise be using Leqembi in the U.S. without this expected increase in usage. This could lead to a rise in the overall quality of life for those individuals affected by the conditions Leqembi is designed to treat.

There is potential for individuals with mild Alzheimer's disease all over the world to benefit from Leqembi. Analysts from the Bank of Montreal and Goldman Sachs have estimated that the drug could bring global yearly sales of up to $15 billion. This suggests the promise of this new medication to those suffering from this degenerative condition.

The impact of this drug could be far-reaching, assisting in improving the quality of life of many individuals. Not only would it help those directly affected by Alzheimer's, but it could also help their families and caregivers by relieving the burden of caring for someone with the disease.

Leqembi could also have a positive economic effect. High annual drug sales could bring much-needed income to the pharmaceutical industry. This increased investment could lead to more research into Alzheimer's and other neurological conditions, allowing for better treatments and improved quality of life.

This news is a massive milestone in the Alzheimer's research field. Aducanumab is biotechnology giant Biogen's first-of-its-kind drug to specifically target and reduce amyloid plaques, which are believed to be the leading cause of Alzheimer's disease. The drug has been under development for around five years and has been tested on thousands of patients. The FDA's approval of Aducanumab is a significant victory for Biogen, and investors wonder if this news is an excellent reason to invest in the company's stock.

The answer to this question rests on the investor's risk profile and investment goals. While Aducanumab's approval is encouraging news for Biogen and its stock, it's essential to consider the company's long-term prospects and financial performance before making a decision. It's also important to note that Aducanumab is far from a sure thing. It's still too early to tell if the drug will successfully treat Alzheimer's disease, and there are no guarantees that it will become a blockbuster drug.

Given the risks involved, it may be best for investors to take a wait-and-see approach. Biogen's stock price has already seen a significant jump in the wake of the news, so investors may want to wait for the hype to die before deciding whether to invest.

That said, the news of Aducanumab's approval still caused optimism. If the drug successfully treats Alzheimer's disease, Biogen's stock could significantly boost. In addition, the company is already exploring other potential uses for the medicine, such as treating Parkinson's disease and multiple sclerosis. This could open up even more revenue streams for Biogen in the future.


For investors willing to take on a higher level of risk, Biogen's stock could be an attractive option. However, it's important to remember that investing in any stock carries inherent risks, and investors should always research and ensure they understand the company's financials before making a decision. The news of Aducanumab's approval is promising, but it's essential to consider all factors before investing in Biogen's stock.

Disclaimer: Our content is intended to be used for informational purposes only. It is essential to do your research before making any investment based on your circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find in this article and wish to rely upon, whether to make an investment decision or otherwise. We do not provide any warranties regarding the information on this website and are not responsible for any losses or damages incurred from trading or investing.

Publisher details:
Company: MK Digiworld


Similar Press Release News

Bit-Galaxy Broker Talks About Cryptocurrencies: A Smart Investment Choice For Long-Term Growth in 2023
By meghana_awhale 01/02/2323

Bit-Galaxy broker Christopher Eddison says it would be hard to argue against the proposition that cryptocurrencies remain the most viable investments in the mod...

Read More
Bit-Galaxy Broker Reports on How To Explore Cryptocurrencies for Potential High Returns in 2023
By meghana_awhale 01/02/2323

Bit-Galaxy broker Damien Richter says the world of cryptocurrency is filled with various opportunities for investors to make high returns. As the years go by an...

Read More
Bit-Galaxy Broker Reports To Invest in Ethereum Now to Take Advantage of Potential Price Increases
By meghana_awhale 01/02/2323

Bit-Galaxy broker Alex Lehner says the next three years are going to be an exciting time for crypto investors. In 2023, most investments will likely still be in...

Read More
Bit-Galaxy Broker Forecasts a Trillion-Dollar Crypto Market in 2023
By meghana_awhale 01/02/2323

Bit-Galaxy broker James Farnworth says the craze for cryptocurrencies of late has been growing sky-high in the past few years — and it’s only going ...

Read More